---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-099376"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T16:56:59.618596+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SAB-142 Phase 1 data shows C-peptide preservation in established T1D patients at Day 120

## Summary
- T1D cohort (n=6): 4 treated with SAB-142 (2.5 mg/kg) showed no decline in C-peptide at Day 120; mean values increased above baseline.
- Placebo participant (n=1) showed C-peptide decline consistent with predicted disease progression.
- Biomarker evidence of T cell exhaustion supports mechanism of action, per KOL Michael Haller, MD.
- SAFEGUARD Phase 2b trial enrolling new-onset Stage 3 T1D patients; topline data expected 2H 2027.
- Phase 1 previously met safety/PD objectives, enabling advancement to registrational trial.

## SEC filing metadata
- accession: 0001193125-26-099376
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000119312526099376/0001193125-26-099376-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000119312526099376/sabs-20260310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-099376
- JSON: https://secwatch.observer/filing/0001193125-26-099376.json
- Plain text: https://secwatch.observer/filing/0001193125-26-099376.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.